iShares MSCI India ETF vs Nuwellis Inc — how do they compare? iShares MSCI India ETF trades at $49.94, while Nuwellis Inc trades at $1.41 (market cap $542.80K). The key difference: iShares MSCI India ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| INDA | NUWE | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $55.29 | $220.50 |
52-Week Low | $45.42 | $1.42 |
Market Cap | — | $542.80K |
Enterprise Value | — | -$1.27M |
Signals from Pluang's Aura AI — not financial advice
INDA trades at $49.95, down 0.38% with a bullish technical signal supported by moving averages. The ETF tracks India's market, which grew 7.8% in Q1 2026 (CNBC, June 5, 2026), but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Key support and resistance cluster around $50.
Outlook remains mixed: India's strong economic growth offers long-term potential, but near-term risks include Middle East disruptions affecting exports (Reuters, August 4, 2026) and AI-driven pressure on IT firms. Institutional sentiment is cautious amid foreign capital rotation.
NUWE trades at $1.41, down 0.7% today, with a bearish technical signal despite oversold RSI readings. The company reported a net loss of $17.52 million on $8.27 million revenue in 2025, with negative cash flow from operations. Recent news highlights expansion in pediatric care and a $3.4 million direct offering in July 2026, alongside a reverse stock split executed in June 2026.
Outlook remains challenged by persistent losses and high cash burn, though revenue growth and product development offer potential. Risks include reliance on financing and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid fundamental weaknesses.
Trailing returns across standard periods
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →